ValuEngine upgraded shares of Aduro BioTech (NASDAQ:ADRO) from a strong sell rating to a sell rating in a report issued on Wednesday.
Several other equities research analysts have also recently issued reports on ADRO. BidaskClub cut shares of Aduro BioTech from a hold rating to a sell rating in a research note on Saturday, December 9th. Oppenheimer set a $15.00 price target on shares of Aduro BioTech and gave the stock a buy rating in a research note on Monday, December 11th. HC Wainwright decreased their price target on shares of Aduro BioTech from $18.00 to $9.50 and set a buy rating on the stock in a research note on Wednesday, December 13th. Canaccord Genuity set a $30.00 target price on shares of Aduro BioTech and gave the stock a buy rating in a research report on Thursday, December 14th. Finally, Cantor Fitzgerald began coverage on shares of Aduro BioTech in a research report on Wednesday, February 21st. They issued an overweight rating and a $15.00 target price on the stock. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $14.50.
Shares of Aduro BioTech (NASDAQ:ADRO) opened at $9.20 on Wednesday. Aduro BioTech has a 12 month low of $5.82 and a 12 month high of $14.05.
In related news, insider Elsas Andrea Van sold 6,874 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $6.48, for a total value of $44,543.52. Following the sale, the insider now directly owns 216,669 shares of the company’s stock, valued at $1,404,015.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Stephen T. Isaacs sold 72,051 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $8.48, for a total transaction of $610,992.48. Following the completion of the sale, the insider now directly owns 231,380 shares in the company, valued at $1,962,102.40. The disclosure for this sale can be found here. Insiders sold 109,758 shares of company stock worth $894,724 over the last three months. Corporate insiders own 6.60% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ADRO. Harvard Management Co. Inc. acquired a new stake in shares of Aduro BioTech in the third quarter worth approximately $69,418,000. Citadel Advisors LLC acquired a new position in Aduro BioTech during the fourth quarter valued at approximately $1,309,000. Goldman Sachs Group Inc. lifted its position in Aduro BioTech by 52.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 294,007 shares of the biotechnology company’s stock valued at $2,205,000 after buying an additional 100,979 shares in the last quarter. Artal Group S.A. lifted its position in Aduro BioTech by 100.0% during the third quarter. Artal Group S.A. now owns 200,000 shares of the biotechnology company’s stock valued at $2,130,000 after buying an additional 100,000 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Aduro BioTech during the third quarter valued at approximately $1,023,000. 44.94% of the stock is currently owned by institutional investors and hedge funds.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.